Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Edgewise Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06066580CT.gov Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | — | Enrolling By Invitation | — | — | — |
NCT05291091CT.gov Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | — | Active Not Recruiting | — | — | — |
NCT05160415CT.gov A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | — | Completed | — | — | — |
NCT04585464CT.gov A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Becker Muscular Dystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sevasemten (this asset) | Edgewise Therapeutics, Inc. | P2 | B · 60 |
| (-)-Epicatechin | Craig McDonald, MD | P2 | BB |
| Carvedilol | Catholic University, Italy | P4 | BB |
| Tadalafil | Cedars-Sinai Medical Center | P4 | BB |
| Ataluren | PTC Therapeutics | P3 | BB |
| Corpril | Catholic University, Italy | P4 | B |
| Lisinopril | Cooperative International Neuromuscular Research Group | P2/3 | B |
| coq10 | Cooperative International Neuromuscular Research Group | P2/3 | B |
| Vamorolone | ReveraGen BioPharma, Inc. | P2 | B |
+10 more in the Becker Muscular Dystrophy cohort
Other indications for Sevasemten
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Duchenne Muscular Dystrophy | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sevasemten in Becker Muscular Dystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sevasemten-becker-muscular-dystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →